Endo International has launched a Peyronie's Self-Assessment app to help men understand and document their condition, Peyronie's Disease (PD), which affects about 1 in 10 men. The app allows users to learn about PD, complete a self-assessment, and locate healthcare providers. It emphasizes empowering men to discuss their symptoms with urologists, addressing the stigma associated with the condition. The app will be presented at the 23rd Annual Fall Scientific Meeting of SMSNA in Miami from October 27-30, 2022.
Endo International plc (OTC: ENDPQ) announced the presentation of five new studies on Qwo® (collagenase clostridium histolyticum-aaes) at the American Society for Dermatologic Surgery meeting in Denver, CO, from October 7-10, 2022. These studies focus on the durability and practical application of Qwo® for treating moderate to severe cellulite in adult women. Important safety information includes potential serious hypersensitivity reactions and common adverse effects such as bruising and pain at injection sites. Qwo® is indicated for cellulite treatment in adult women.
Endo International plc (OTC: ENDPQ) launched a video series titled Coffee & Cords to educate audiences about Dupuytren's contracture (DC), a hand condition affecting around 14 million Americans. The series features real patients discussing their experiences and treatment options, particularly the use of XIAFLEX, the only FDA-approved nonsurgical treatment. The videos are hosted on the redesigned XIAFLEX website and will be promoted through digital and social ads later this year.